Form 4: Colgate-Palmolive Director Brian Newman Reports Stock and Option Grants

Director Brian Newman reports annual stock and option grants from Colgate-Palmolive, along with a clarification regarding shares held in a family trust.

Summary

• On May 13, 2024, Brian Newman, a director of Colgate-Palmolive, reported transactions involving the company's stock.
• Newman received 1,587 shares of common stock as an annual director stock grant under the issuer's incentive compensation plan.
• He also received an annual director stock option grant for 1,834 shares with an exercise price of $94.46, exercisable in equal annual installments over three years starting May 13, 2025.
• Additionally, the filing clarifies that 36 shares previously reported as directly owned are held by a Family Trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard director compensation practices, which are generally viewed favorably as aligning management and shareholder interests.

Positives

• The director's receipt of stock and option grants aligns with the company's incentive compensation plan, potentially motivating performance.
• The vesting schedule of the options encourages long-term commitment from the director.

Future Outlook

The director's future beneficial ownership will change as the options vest and are potentially exercised.

Industry Context

Director compensation in the form of stock and options is a common practice among publicly traded companies to align the interests of management with those of shareholders.

Comparison to Industry Standards

• Comparing Colgate-Palmolive's director compensation structure with peers like Procter & Gamble (PG) and Unilever (UL) would provide a benchmark for assessing the competitiveness and appropriateness of the grants.
• Analyzing the vesting schedules and exercise prices of options granted to directors in similar consumer goods companies can offer insights into industry norms.
• Benchmarking the total equity compensation as a percentage of overall compensation against industry averages can help determine if Colgate-Palmolive's approach is in line with market practices.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning the director's interests with the company's long-term performance.
• The grants could potentially impact the company's earnings per share if the options are exercised.

Key Dates